CD19 and non-Hodgkin lymphoma: In particular, the CD19 antibody MOR208 provided initial evidence for clinical activity in a phase I dose-escalation study in patients with relapsed or refractory CLL/SLL [7], as well as in the phase IIa NHL study in which our patient is enrolled [16].